Business
Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting
Additional data from the Phase 2 ARCHER trial demonstrating protection of visual acuity and anatomical structure following ANX007 treatment will be featured
About this update from Annexon, Inc.
[{"type":"text","content":"Additional data from the Phase 2 ARCHER trial demonstrating protection of visual acuity and anatomical structure following ANX007 treatment will be featured as an oral presentation New preclinical data on the pathogenic role of C1q on photoreceptor synapse elimination and the protection of photoreceptors and their function from C1q blockade in GA will be featured as a poster presentation BRISBANE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced the Company will have two presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held May 5-9, 2024 in Seattle, Washington. Additional Phase 2 clinical results of ANX007 from the ARCHER trial in geographic atrophy (GA), including further analyses of visual acuity and photoreceptor preservation, will be presented as an oral presentation. Also, new preclinical data on the role of C1q in the pathogenic elimination of photoreceptor synapses and protection of photoreceptors and their function with C1q blockade in GA will be presented as a poster presentation. Details of the presentations are as follows: Oral Presentation: “Protection Against Vision Loss by ANX007: Results from the Phase 2 ARCHER Clinical Trial” Abstract #: 2791Session: AMD; Clinical research IIPresenter: Dr. David S. Boyer, Retina-Vitreous Associates Medical Group, CaliforniaDate/Time: Tuesday, May 7, 2024, 9:15 – 9:30 a.m. PTLocation: Seattle Convention Center, Arch Building Room 612 Poster Presentation: “C1q inhibition protects photoreceptor synapses and preserves retinal function in a preclinical model of photoreceptor degeneration” Abstract #: 3944Session: Neuroprotection in the retinaPresenter: Dr. Alessia Tassoni, Associate Director at Annexon BiosciencesDate/Time: Tuesday, May 7, 2024, 3:30 – 5:15 p.m. PTLocation: Seattle Convention Center, Arch Building, Exhibit Hall, Posterboard #A0463 Additional presentation details and abstracts are available on the ARVO 2024 website here. About ANX007 and Phase 2 ARCHER TrialANX007 is a fragment antigen-binding (fab) antibody designed as a first-in-kind therapeutic to selectively inhibit C1q,...